University of Washington presents the June 2018 Obstetric Consensus Conference with Alisa Kachikis, MD, Terry Gernsheimer, MD, and Shani Delaney, MD. The objective is to evaluate the use of TXA for prevention and treatment of postpartum hemorrhage (PPH) in the obstetric setting.
Postpartum hemorrhage continues to be a major cause of maternal mortality worldwide (1). In recent years, tranexamic acid (TXA), an antifibrinolytic agent, has received increased global attention from the obstetrics community in the effort to decrease maternal mortality due to postpartum hemorrhage.
